Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
ALK translocation
i
Other names:
NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
238
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
EML4-ALK variant 3 + TP53 mutation (5)
ALK fusion + ALK G1202R (4)
TP53 mutation + ALK positive (4)
ALK rearrangement + MET amplification (3)
EGFR wild-type + ALK wild-type + PD-L1 expression (3)
EML4-ALK fusion + ALK F1174L + ALK S1189C (3)
EML4-ALK fusion + ALK positive (3)
PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L (3)
RANBP2-ALK rearrangement + TNFRSF8 expression (3)
ALK fusion + TP53 mutation (2)
ALK positive + ALK mutation (2)
ALK rearrangement + PD-L1 overepxression (2)
EML4-ALK + ALK G1202R + LIPI-NTRK1 (2)
EML4-ALK fusion + ALK G1202R (2)
EML4-ALK fusion + ALK rearrangement (2)
EML4-ALK fusion + TP53 mutation (2)
EML4-ALK gene fusion + EGFR exon 19 deletion + EGFR T790M + EGFR C797G (2)
MYC amplification + ALK F1174L (2)
MYCN amplification + ALK F1174V (2)
MYCN amplification + ALK rearrangement (2)
STRN-ALK fusion + MET amplification (2)
ALK exon 23 C1156Y missense mutation+ LOC101927285-ALK fusion (1)
ALK expression + RSRC1-ALK fusion (1)
ALK fusion + ALK G1269A (1)
ALK fusion + ALK I1179T (1)
ALK fusion + ALK V1180L (1)
ALK fusion + EGFR exon 19 deletion + BRAF G466V + MAP2K1 F129L (1)
ALK fusion + EML4-ALK variant 3 + TP53 mutation (1)
ALK fusion + FAT3 mutation (1)
ALK fusion + FAT4 mutation (1)
ALK fusion + MYC amplification + CCND1 deletion + FGFR3 deletion (1)
ALK mutation + TMB-H (1)
ALK negative + S100A8 elevation (1)
ALK negative + S100A9 elevation (1)
ALK negative + SAA1 elevation (1)
ALK negative + SAA2 elevation (1)
ALK negative + TP53 deletion (1)
ALK positive + ALK G1202R (1)
ALK positive + ALK G1202R + ALK L1196M (1)
ALK positive + ALK L1196M + ALK D1203N (1)
ALK positive + DNMT3A N403Tfs* (1)
ALK positive + EML4-ALK fusion + TP53 mutation (1)
ALK positive + ERCC3 E259D + GNAS A436_P459del (1)
ALK positive + MYC amplification + CCND1 deletion (1)
ALK psoitive + ALK G1202R + ALK F1174C (1)
ALK rearrangement + ABCC11 overexpression (1)
ALK rearrangement + ALK I1171N + ALK V1180L + BRCA2 F2801fs (1)
ALK rearrangement + BRCA2 F2801fs (1)
ALK rearrangement + CDKN2A deletion (1)
ALK rearrangement + CDKN2B deletion (1)
ALK rearrangement + CTLA4 overexpression (1)
ALK rearrangement + EML4-ALK fusion + CCDC148-ALK fusion + PKDCC-ALK fusion + VIT-ALK fusion (1)
ALK rearrangement + MET amplification (1)
ALK wild-type + NT5E overexpression + PD-L1 expression (1)
ALK-EML4_V3a + PD-L1 overexpression (1)
ALK-EML4_V3b + PD-L1 overexpression (1)
BCL2L11 deletion + ALK positive (1)
CPE-ALK fusion + TP53 wild-type (1)
EGFR T790M + STRN-ALK fusion + EGFR amplification + MET amplification (1)
EGFR exon 19 deletion + STRN-ALK fusion (1)
EGFR mutation + ALK negative + TMB-H (1)
EGFR negative + ALK negative + PD-L1 expression (1)
EGFR wild-type + ALK wild-type + NT5E overexpression + PD-L1 expression (1)
EML4-ALK fusion + ALK I1171N (1)
EML4-ALK fusion + ALK I1171T (1)
EML4-ALK fusion + NFKBIA amplification + NKX2-1 amplification (1)
EML4-ALK fusion + TMB-L (1)
EML4-ALK fusion v1insLTBP1 (1)
IDH2 mutation + ALK fusion (1)
KIF5B-ALK fusion + ALK L1196M (1)
MET amplification + KLC1-ALK fusion (1)
MET exon 14 mutation + ALK wild-type (1)
MYCN amplification + ALK F1174L (1)
MYCN amplification + ALK R1275Q (1)
PIK3CA mutation + ALK fusion (1)
PIK3CA mutation + ALK positive (1)
PTEN mutation + ALK positive (1)
SLC8A1-PKDCC-ALK fusion + ALK overexpression (1)
SMARCA4 mutation + ALK positive (1)
STRN-ALK fusion + EML4-ALK fusion + EGFR T790M (1)
STRN-ALK fusion + KRAS G13D (1)
TMB-H + ALK rearrangement (1)
TPM3-NTRK1 fusion + ALK L1196M (1)
PD-L1 underexpression + ALK wild-type (0)
EML4-ALK variant 3 + TP53 mutation (5)
ALK fusion + ALK G1202R (4)
TP53 mutation + ALK positive (4)
ALK rearrangement + MET amplification (3)
EGFR wild-type + ALK wild-type + PD-L1 expression (3)
EML4-ALK fusion + ALK F1174L + ALK S1189C (3)
EML4-ALK fusion + ALK positive (3)
PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L (3)
RANBP2-ALK rearrangement + TNFRSF8 expression (3)
ALK fusion + TP53 mutation (2)
ALK positive + ALK mutation (2)
ALK rearrangement + PD-L1 overepxression (2)
EML4-ALK + ALK G1202R + LIPI-NTRK1 (2)
EML4-ALK fusion + ALK G1202R (2)
EML4-ALK fusion + ALK rearrangement (2)
EML4-ALK fusion + TP53 mutation (2)
EML4-ALK gene fusion + EGFR exon 19 deletion + EGFR T790M + EGFR C797G (2)
MYC amplification + ALK F1174L (2)
MYCN amplification + ALK F1174V (2)
MYCN amplification + ALK rearrangement (2)
STRN-ALK fusion + MET amplification (2)
ALK exon 23 C1156Y missense mutation+ LOC101927285-ALK fusion (1)
ALK expression + RSRC1-ALK fusion (1)
ALK fusion + ALK G1269A (1)
ALK fusion + ALK I1179T (1)
ALK fusion + ALK V1180L (1)
ALK fusion + EGFR exon 19 deletion + BRAF G466V + MAP2K1 F129L (1)
ALK fusion + EML4-ALK variant 3 + TP53 mutation (1)
ALK fusion + FAT3 mutation (1)
ALK fusion + FAT4 mutation (1)
ALK fusion + MYC amplification + CCND1 deletion + FGFR3 deletion (1)
ALK mutation + TMB-H (1)
ALK negative + S100A8 elevation (1)
ALK negative + S100A9 elevation (1)
ALK negative + SAA1 elevation (1)
ALK negative + SAA2 elevation (1)
ALK negative + TP53 deletion (1)
ALK positive + ALK G1202R (1)
ALK positive + ALK G1202R + ALK L1196M (1)
ALK positive + ALK L1196M + ALK D1203N (1)
ALK positive + DNMT3A N403Tfs* (1)
ALK positive + EML4-ALK fusion + TP53 mutation (1)
ALK positive + ERCC3 E259D + GNAS A436_P459del (1)
ALK positive + MYC amplification + CCND1 deletion (1)
ALK psoitive + ALK G1202R + ALK F1174C (1)
ALK rearrangement + ABCC11 overexpression (1)
ALK rearrangement + ALK I1171N + ALK V1180L + BRCA2 F2801fs (1)
ALK rearrangement + BRCA2 F2801fs (1)
ALK rearrangement + CDKN2A deletion (1)
ALK rearrangement + CDKN2B deletion (1)
ALK rearrangement + CTLA4 overexpression (1)
ALK rearrangement + EML4-ALK fusion + CCDC148-ALK fusion + PKDCC-ALK fusion + VIT-ALK fusion (1)
ALK rearrangement + MET amplification (1)
ALK wild-type + NT5E overexpression + PD-L1 expression (1)
ALK-EML4_V3a + PD-L1 overexpression (1)
ALK-EML4_V3b + PD-L1 overexpression (1)
BCL2L11 deletion + ALK positive (1)
CPE-ALK fusion + TP53 wild-type (1)
EGFR T790M + STRN-ALK fusion + EGFR amplification + MET amplification (1)
EGFR exon 19 deletion + STRN-ALK fusion (1)
EGFR mutation + ALK negative + TMB-H (1)
EGFR negative + ALK negative + PD-L1 expression (1)
EGFR wild-type + ALK wild-type + NT5E overexpression + PD-L1 expression (1)
EML4-ALK fusion + ALK I1171N (1)
EML4-ALK fusion + ALK I1171T (1)
EML4-ALK fusion + NFKBIA amplification + NKX2-1 amplification (1)
EML4-ALK fusion + TMB-L (1)
EML4-ALK fusion v1insLTBP1 (1)
IDH2 mutation + ALK fusion (1)
KIF5B-ALK fusion + ALK L1196M (1)
MET amplification + KLC1-ALK fusion (1)
MET exon 14 mutation + ALK wild-type (1)
MYCN amplification + ALK F1174L (1)
MYCN amplification + ALK R1275Q (1)
PIK3CA mutation + ALK fusion (1)
PIK3CA mutation + ALK positive (1)
PTEN mutation + ALK positive (1)
SLC8A1-PKDCC-ALK fusion + ALK overexpression (1)
SMARCA4 mutation + ALK positive (1)
STRN-ALK fusion + EML4-ALK fusion + EGFR T790M (1)
STRN-ALK fusion + KRAS G13D (1)
TMB-H + ALK rearrangement (1)
TPM3-NTRK1 fusion + ALK L1196M (1)
PD-L1 underexpression + ALK wild-type (0)
›
Related tests:
Lung Cancer 8-Gene Kit
Lung Cancer 8-Gene Kit
Associations
(9)
News
Trials
Search handles
@CharuAggarwalMD
@FordePatrick
@Jbauml
@UroDocAsh
@ViktorGruenwald
@VinciusLorandi1
@montypal
Search handles
@CharuAggarwalMD
@FordePatrick
@Jbauml
@UroDocAsh
@ViktorGruenwald
@VinciusLorandi1
@montypal
Filter by
Latest
over1year
Pt in her early 40s, extensively metastatic lung cancer, “no target” on a few diff attempts at DNA seq (editorializing - please don’t biopsy bone for lung cancer diagnosis!) or liquid biopsy, repeat tissue biopsy & RNA seq = EML4-ALK translocation! Christmas came early! #lcsm (@FordePatrick)
over 1 year ago
Liquid biopsy
|
ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4)
|
ALK translocation
over1year
Very nice tool for selecting treatment for both ALK and ROS translocations #NSCLC #lungcancer #gbot https://t.co/Otzs3Gqr6A (@VinciusLorandi1)
over 1 year ago
ALK (Anaplastic lymphoma kinase)
|
ALK translocation
over1year
Very nice tool for selecting treatment for both ALK and ROS translocations #NSCLC #lungcancer #gbot https://t.co/Otzs3GpTh2 (@VinciusLorandi1)
over 1 year ago
ALK (Anaplastic lymphoma kinase)
|
ALK translocation
almost2years
👏 to Holger and colegues. New classification of RCC: 👉New morphological entity: eosinophilic & cystic RCC 👉New molecular-defined RCC: ELOC-mutated, ALK-translocation, SMARCB1, TFEB-altered, FH-deficient 👉New: pRCC is 1 entity only https://t.co/bdjyk1OBPf (@ViktorGruenwald)
almost 2 years ago
ALK (Anaplastic lymphoma kinase) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • TFEB (Transcription Factor EB 2)
|
ALK translocation
over2years
Our series supports organ sparing therapy for patients with localized inflammatory myofibroblastic tumors of the bladder. Extirpative surgery only for refractory cases; crizotinib for metastatic disease with ALK translocation https://t.co/EJ3co2O1Ut @pjhensley11 @CurtisPettaway1 (@UroDocAsh)
over 2 years ago
Clinical
|
ALK (Anaplastic lymphoma kinase)
|
ALK translocation
|
Xalkori (crizotinib)
over2years
Our real world analysis of the prevalence of ALK translocations. While rare, 21.6% of young pts with lung cancer had an ALK mutation. Biomarker panel testing is necessary and urgent at diagnosis. #LCSM #ALK hahttps://www.oncotarget.com/article/28114/text/#.YY0laOE_zMo.twitter (@EricBernicker)
over 2 years ago
Clinical • Real-world evidence
|
ALK (Anaplastic lymphoma kinase)
|
ALK translocation
over2years
About 5% of tumors are ALK which are generally tic inversions or translocations in #lungcancer says @GRSimonMD with cochairs @edgardo_ny @LuisERaez1 and Dr Chiappori @OncLiveSOSS #ipc #lcsm @AdventHealth @MoffittNews (@donnashort)
over 2 years ago
ALK (Anaplastic lymphoma kinase)
|
ALK translocation
3years
NEED HELP: writing commentary on ALK-directed tx in non-NSCLC tumors. Anytone know if @theNCI MATCH trial arm for ALK translocation has been reported? Per websute seems like accrual complete in 2015. Also for @EORTC CREATE, anyone know where the non-PRCC type1 arms are published? (@montypal)
3 years ago
ALK (Anaplastic lymphoma kinase)
|
ALK translocation
over3years
These curves are the difference in OS outcomes based on out of pocket costs for #LungCancer w/ #EGFR Mt or #ALK translocations. Small numbers, but these data are very instructive. We need to support our pts better @EGFRResisters @ALKLungCancer @alk_fusion @ASCO_pubs #JCOOP #LCSM (@CharuAggarwalMD)
over 3 years ago
Clinical
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
ALK fusion • ALK translocation
almost4years
We now have two FDA approved treatments for the 1L management of NSCLC harboring an ALK translocation. This is an interesting one - the toxicity profile of the two drugs is very different in my experience, so there could be a role for both here. (@Jbauml)
almost 4 years ago
FDA event
|
ALK (Anaplastic lymphoma kinase)
|
ALK translocation
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login